Pro-inflammatory cytokine and soluble mediator

Pro-inflammatory cytokines and soluble mediators are a diverse group of signaling proteins and small molecules secreted by immune cells, such as macrophages and T-cells, to orchestrate the inflammatory response (StatPearls, 2023). This broad category includes tumor necrosis factors (TNF), interleukins (e.g., IL-1, IL-6), and chemokines, which facilitate leukocyte recruitment and activation at sites of infection or injury (NIH, 2022). While essential for host defense, the dysregulated or chronic production of these mediators is a central driver in the pathogenesis of various inflammatory and autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and cytokine release syndrome (PubMed, 2021). Therapeutic strategies targeting this group involve the use of biologics, such as monoclonal antibodies (e.g., infliximab, tocilizumab) or decoy receptors (e.g., etanercept), which neutralize specific cytokines or block their receptors to attenuate systemic inflammation (Nature Reviews Drug Discovery, 2020). Because these mediators are integral to normal immune function, their pharmacological inhibition carries significant risks, most notably an increased susceptibility to serious opportunistic infections (FDA, 2023).

Other names

Inflammatory cytokinesPro-inflammatory mediatorsInflammatory signaling moleculesSoluble inflammatory factors

Neutralization of circulating ligands or competitive inhibition of their cognate receptors to prevent downstream intracellular signaling cascades such as the JAK-STAT or NF-κB pathways (Nature Reviews Drug Discovery, 2020).